Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Weight Gain 1Overweight 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sucrose × Endocrine × Clear all
NCT04804397 2021-03-18

Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

University of Hull

Phase NA Completed
80 enrolled
Endocrine

Weight Gain, Multiple Endocrine Neoplasia Type 1, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡